Martine J. van Vugt

Member of the Board of Directors since April 2022

Education: PhD

Background: +20 years of biotechnology industry experience and is a proven leader with a successful track record of leading high-performing, global cross-functional teams in a networked biotech environment. She is skilled in developing joint business value propositions, designing partnership structures and management of alliances. Martine is an expert in corporate transactional and licensing operations, including strategic partnering, in- and out-licensing as well as asset divestment and purchases.
She is recognized internally and in industry for her strong leadership, communication and negotiation skills, and effectively blends analytical skills with a natural leadership style grounded in integrity and science. Martine is an inventor of Darzalex ® and Tepezza.

Other ongoing assignments: Executive Vice President & Chief Strategy Officer at Genmab.

Independence: Independent in relation to both the Company and executive management.

Scandion Oncology shares and warrants:
64.271 warrants.